James Arthos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Arthos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Aftab A. Ansari
Department of Pathology, Emory University School of Medicine, Atlanta, GA, 30322, USA
2 shared publicationsAnthony S. Fauci
Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA
2 shared publicationsClaudia Cicala
Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA
2 shared publicationsFatima Nawaz
Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA
2 shared publicationsFrancois Villinger
New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, 70560, USA
2 shared publicationsAlia Sajani
Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA
1 shared publication
Latest Publications
- Open Access
- 6 June 2018
- Published by Elsevier in Mucosal Immunology
- Vol. 11 (5) , 1342-1351
MAdCAM costimulation through Integrin-α4β7 promotes HIV replication
- 6 June 2018
- Published by Elsevier in Mucosal Immunology
- Vol. 11 (5) , 1342-1351
Open AccessMAdCAM costimulation through Integrin-α4β7 promotes HIV replication
- Open Access
- 24 February 2018
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 15 (2) , 127-135
The Role of Integrin α4β7 in HIV Pathogenesis and Treatment
Purpose of Review Acute HIV infection is characterized by high-level viral replication throughout the body’s lymphoid system, particularly in gut-associated lymphoid tissues resulting in damage to structural components of gut tissue. This damage is irreversible and believed to contribute to the development of immune deficiencies. Antiretroviral therapy (ART) does not restore gut structure and function. Studies in macaques point to an alternative treatment strategy that may ameliorate gut damage. Integrin α4β7 mediates the homing of lymphocytes to gut tissues. Vedolizumab, a monoclonal antibody (mAb) antagonist of α4β7, has demonstrated efficacy and has been approved for the treatment of inflammatory bowel disease in humans. Here, we describe our current knowledge, and the gaps in our understanding, of the role of α4β7 in HIV pathogenesis and treatment. Recent Findings When administered to macaques prior to infection, a nonhuman primate analogue of vedolizumab prevents transmission of SIV. In combination with ART, this mAb facilitates durable virologic control following treatment interruption. Summary Targeting α4β7 represents a novel therapeutic approach to prevent and treat HIV infection.
- 24 February 2018
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 15 (2) , 127-135
Open AccessThe Role of Integrin α4β7 in HIV Pathogenesis and Treatment
Purpose of Review Acute HIV infection is characterized by high-level viral replication throughout the body’s lymphoid system, particularly in gut-associated lymphoid tissues resulting in damage to structural components of gut tissue. This damage is irreversible and believed to contribute to the development of immune deficiencies. Antiretroviral therapy (ART) does not restore gut structure and function. Studies in macaques point to an alternative treatment strategy that may ameliorate gut damage. Integrin α4β7 mediates the homing of lymphocytes to gut tissues. Vedolizumab, a monoclonal antibody (mAb) antagonist of α4β7, has demonstrated efficacy and has been approved for the treatment of inflammatory bowel disease in humans. Here, we describe our current knowledge, and the gaps in our understanding, of the role of α4β7 in HIV pathogenesis and treatment. Recent Findings When administered to macaques prior to infection, a nonhuman primate analogue of vedolizumab prevents transmission of SIV. In combination with ART, this mAb facilitates durable virologic control following treatment interruption. Summary Targeting α4β7 represents a novel therapeutic approach to prevent and treat HIV infection.